José Marco-Contelles Selected Research

Rotenone

8/2021	Privileged Quinolylnitrones for the Combined Therapy of Ischemic Stroke and Alzheimer's Disease.
2/2021	Synthesis, Neuroprotection, and Antioxidant Activity of 1,1'-Biphenylnitrones as α-Phenyl-N-tert-butylnitrone Analogues in In Vitro Ischemia Models.
1/2020	Synthesis, antioxidant properties and neuroprotection of α-phenyl-tert-butylnitrone derived HomoBisNitrones in in vitro and in vivo ischemia models.
4/2019	QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer's Disease Therapy.
10/2016	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
1/2011	Synthesis, structure, theoretical and experimental in vitro antioxidant/pharmacological properties of α-aryl, N-alkyl nitrones, as potential agents for the treatment of cerebral ischemia.
1/2011	Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles.
8/2010	Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles.
7/2010	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José Marco-Contelles Research Topics

Disease

70	Alzheimer Disease (Alzheimer's Disease) 11/2021 - 12/2006
11	Neuroblastoma 03/2022 - 12/2006
9	Stroke (Strokes) 08/2021 - 01/2012
8	Ischemia 07/2022 - 09/2012
8	Brain Ischemia (Cerebral Ischemia) 06/2022 - 01/2011
8	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2022 - 07/2014
5	Ischemic Stroke 06/2022 - 10/2017
4	Infarction (Infarctions) 07/2022 - 01/2020
4	Cognitive Dysfunction 01/2020 - 07/2014
4	Amyloid Plaque 01/2020 - 01/2016
3	Inflammation (Inflammations) 12/2018 - 05/2013
3	Neuroinflammatory Diseases 12/2018 - 01/2016
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2022 - 10/2017
2	Gliosis 01/2020 - 07/2014
2	Parkinson Disease (Parkinson's Disease) 02/2015 - 07/2014
2	Dementia (Dementias) 07/2014 - 12/2007
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 06/2013 - 01/2011
2	Vascular Diseases (Vascular Disease) 01/2011 - 08/2010
1	Gout 01/2022
1	Hearing Loss (Hearing Impairment) 01/2021
1	Hypoxia (Hypoxemia) 03/2020
1	Necrosis 05/2019
1	Reperfusion Injury 10/2017
1	Brain Injuries (Brain Injury) 01/2017

Drug/Important Bio-Agent (IBA)

25	AntioxidantsIBA 07/2022 - 01/2011
20	Biological ProductsIBA 08/2021 - 09/2011
17	Tacrine (Cognex)FDA Link 01/2021 - 12/2006
14	LigandsIBA 01/2021 - 05/2009
14	Cholinesterases (Cholinesterase)IBA 01/2021 - 12/2011
13	nitronesIBA 06/2022 - 01/2011
13	Monoamine Oxidase (MAO)IBA 01/2021 - 09/2011
10	Neuroprotective AgentsIBA 07/2022 - 12/2006
10	N- ((5- (3- (1- benzylpiperidin- 4- yl)propoxy)- 1- methyl- 1H- indol- 2- yl)methyl)- N- methylprop- 2- yn- 1- amineIBA 01/2020 - 10/2013
9	Pharmaceutical PreparationsIBA 06/2022 - 09/2011
9	RotenoneIBA 08/2021 - 07/2010
9	oligomycin AIBA 08/2021 - 07/2010
8	Cholinesterase Inhibitors (Anticholinesterases)IBA 11/2021 - 09/2011
8	Donepezil (Aricept)FDA LinkGeneric 08/2018 - 12/2011
7	Oxygen (Dioxygen)IBA 06/2022 - 09/2012
7	Glucose (Dextrose)FDA LinkGeneric 06/2022 - 09/2012
6	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA 11/2020 - 12/2011
6	Cholinergic Agents (Cholinergics)IBA 01/2019 - 12/2007
6	MelatoninIBA 01/2017 - 01/2016
5	Calcium Channels (Calcium Channel)IBA 01/2021 - 06/2011
5	propargylamineIBA 01/2020 - 06/2014
5	Oxidoreductases (Dehydrogenase)IBA 01/2020 - 06/2012
5	AminesIBA 01/2017 - 12/2011
4	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2022 - 05/2013
4	Amyloid (Amyloid Fibrils)IBA 08/2021 - 01/2016
4	AcetylcholinesteraseIBA 05/2020 - 12/2006
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2015
3	Superoxides (Superoxide)IBA 03/2022 - 01/2020
3	Okadaic AcidIBA 08/2021 - 10/2016
3	Free RadicalsIBA 11/2020 - 12/2006
3	OxidesIBA 11/2020 - 09/2012
3	1,4-dihydropyridine (dihydropyridine)IBA 10/2020 - 12/2006
3	Scopolamine (Hyoscine)FDA Link 01/2020 - 01/2016
3	EnzymesIBA 01/2016 - 06/2012
2	cholesteronitroneIBA 07/2022 - 03/2020
2	Hydroxyl RadicalIBA 03/2022 - 01/2020
2	purineIBA 03/2022 - 01/2015
2	Peptides (Polypeptides)IBA 08/2021 - 07/2020
2	phenyl-N-tert-butylnitroneIBA 02/2021 - 01/2020
2	Dihydrotachysterol (AT 10)IBA 10/2020 - 03/2020
2	Amyloid beta-PeptidesIBA 07/2020 - 08/2016
2	Therapeutic UsesIBA 03/2020 - 01/2017
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2020 - 01/2017
2	MetalsIBA 01/2020 - 06/2014
2	quinolineIBA 08/2016 - 01/2012
2	N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamineIBA 01/2016 - 07/2014
1	BoratesIBA 07/2022
1	pyrimidineIBA 03/2022
1	Lipoxygenase (Lipoxygenase-1)IBA 03/2022
1	InflammasomesIBA 01/2022
1	calcipotriene (calcipotriol)FDA LinkGeneric 08/2021
1	Glycogen Synthase KinasesIBA 01/2021
1	tetramethylpyrazineIBA 11/2020
1	3-n-butylphthalide (butylphthalide)IBA 11/2020
1	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 07/2020
1	QuinolonesIBA 05/2020
1	Free Radical ScavengersIBA 03/2020
1	pyridineIBA 03/2020
1	IronIBA 01/2020
1	Mitochondrial Permeability Transition PoreIBA 01/2020
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020
1	Protein Kinase CIBA 01/2020
1	Histamine H3 Receptors (Histamine H3 Receptor)IBA 12/2019
1	LipopolysaccharidesIBA 12/2019
1	6- hydroxy- 2,5,7,8- tetramethylchroman- 2- carboxylic acid (Trolox)IBA 10/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 03/2019
1	Type I Tumor Necrosis Factor ReceptorsIBA 12/2018
1	Histamine (Histamine Dihydrochloride)FDA Link 10/2017
1	CurcuminIBA 01/2017
1	BerberineIBA 01/2017
1	Serotonin ReceptorsIBA 01/2017
1	Tamoxifen FDA LinkGeneric 01/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017
1	Formaldehyde (Formol)FDA Link 11/2016

Therapy/Procedure

37	Therapeutics 08/2021 - 09/2011
1	Intravenous Administration 06/2022